CSFB Initiates Kosan With Outperform

Analyst Michele Park notes potential for the development-stage biotech company with over $200 million market cap

CS First Boston initiates Kosan Biosciences (KOSN ) coverage with outperform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.